Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Short excerpt below. Click through to read at the original source.
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.